Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda

Kineta, Inc. struck a collaboration deal with Merck to pair its anti-VISTA monoclonal antibody with Keytruda (pembrolizumab) as a potential treatment for advanced solid tumors, the companies announced Monday.